1.
Börjesson, J., et al.
(författare)
X-ray fluorescence analysis in medical sciences: A review
2003
Ingår i: Acta Diabetologica. - : Springer Science and Business Media LLC. - 0940-5429 .- 1432-5233. ; 40
Tidskriftsartikel (refereegranskat) abstract
Some elements have toxic effects on the human body and there is thus a need to control their levels in human organs and tissues. Moreover, it is important to increase our knowledge of relationships between observable toxic effects and element concentrations in man and his environment. Monitoring and basic occupational and environmental research rely on measurements directly in humans as well as samples from humans and the environment. This paper reviews recent advances in in vivo X-ray fluorescence methods and their applications.
2.
3.
Areberg, Johan, et al.
(författare)
Antitumor effect of radioactive cisplatin (191Pt) on nude mice
2001
Ingår i: International Journal of Radiation Oncology, Biology, Physics. - 0360-3016. ; 49:3, s. 827-832
Tidskriftsartikel (refereegranskat) abstract
PURPOSE: To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice. METHODS AND MATERIALS: Tumor-bearing (human squamous cell carcinoma, AB) nude mice were divided into four groups and given, i.p., physiological saline (controls), cisplatin, (191)Pt-cisplatin (80 MBq/mg), or (191)Pt-cisplatin (160 MBq/mg), respectively. Mortality and weight were used as parameters for monitoring general toxic effect, while specific growth delay (SGD) and the area under the logarithm of the relative tumor size curve (AUC-log[RTS]) were used to evaluate the antitumor effect of the treatments. RESULTS: Both SGD and AUC-log(RTS) values showed that (191)Pt-cisplatin was significantly (P < 0.05) more effective in retarding tumor growth than nonradioactive cisplatin. No differences in mortality between the different groups could be observed and no significant differences in weight change between the mice treated with cisplatin or (191)Pt-cisplatin could be seen. CONCLUSION: (191)Pt-cisplatin is a more effective drug than nonradioactive cisplatin in retarding tumor growth on nude mice without adding systemic toxic effects. We believe that radioactive cisplatin may prove to be an alternative to conventional cisplatin; however, the possible toxic effects on organs at risk have to be thoroughly investigated.
4.
Aznar, MC, et al.
(författare)
Real-time optical-fibre luminescence dosimetry for radiotherapy: physical characteristics and applications in photon beams
2004
Ingår i: Physics in Medicine and Biology. - : IOP Publishing. - 1361-6560 .- 0031-9155. ; 49:9, s. 1655-1669
Tidskriftsartikel (refereegranskat) abstract
A new optical-fibre radiation dosimeter system, based on radioluminescence and optically stimulated luminescence from carbon-doped aluminium oxide, was developed and tested in clinical photon beams. This prototype offers several features, such as a small detector (1 x 1 x 2 mm), high sensitivity, real-time read-out and the ability to measure both dose rate and absorbed dose. The measurements describing reproducibility and output dependence on dose rate, field size and energy all had standard deviations smaller than 1%. The signal variation with the angle of incidence was smaller than 2% (1 SD). Measurements performed in clinical situations suggest the potential of using this real-time system for in vivo dosimetry in radiotherapy.
5.
6.
Börjesson, Jimmy, et al.
(författare)
Kidney cadmium as compared to other markers of cadmium exposure in workers at a secondary metal smelter
2001
Ingår i: American Journal of Industrial Medicine. - 0271-3586. ; 39:1, s. 19-28
Tidskriftsartikel (refereegranskat) abstract
BACKGROUND: The aim of the study was to evaluate whether cadmium concentrations in kidney (K-Cd), blood (B-Cd) or urine (U-Cd) could reveal previous occupational cadmium exposure at a metal smelter. METHODS: The study included 90 smelters and 35 controls (B-Cd and U-Cd determination). In a subgroup (N = 33), K-Cd was also determined. RESULTS: B-Cd (median 4.6; range 0.5-53 nmol/L), U-Cd (0. 29; 0.04-1.9 micromol/mol creatinine) and K-Cd (14; 3-61 microg/g wet weight) were similar to reported concentrations in the general Swedish population. In the subgroup, significant associations (P<0. 001) were obtained between B-Cd and K-Cd (r = 0.70), U-Cd and K-Cd (r = 0.60) and between U-Cd and B-Cd (r = 0.62). Multiple regression analyses revealed smoking as the major predictor of K-Cd, B-Cd, and U-Cd. B-Cd and U-Cd were both associated with the duration of employment at the smelter. CONCLUSIONS: There was no statistically significant evidence of previous occupational exposure at the smelter from measurement of K-Cd.
7.
8.
9.
10.
Gunnarsson, Mikael, et al.
(författare)
No radiation protection reasons for restrictions on C-14 urea breath tests in children.
2002
Ingår i: British Journal of Radiology. - : British Institute of Radiology. - 1748-880X .- 0007-1285. ; 75:900, s. 982-986
Tidskriftsartikel (refereegranskat) abstract
Traditional 14C urea breath tests are normally not used for younger children because the radiation exposure is unknown. High sensitivity accelerator mass spectrometry and an ultra-low amount (440 Bq) of 14C urea were therefore used both to diagnose Helicobacter pylori (HP) infection in seven children, aged 3–6 years, and to make radiation dose estimates. The activity used was 125 times lower than the amount normally used for older children and 250 times lower than that used for adults. Results were compared with previously reported biokinetic and dosimetric data for adults and older children aged 7–14 years. 14C activity concentrations in urine and exhaled air per unit administered activity for younger children (3–6 years) correspond well with those for older children (7–14 years). For a child aged 3–6 years who is HP negative, the urinary bladder wall receives the highest absorbed dose, 0.3 mGy MBq-1. The effective dose is 0.1 mSv MBq-1 for the 3-year-old child and 0.07 mSv MBq-1 for the 6-year-old child. For two children, the 10 min and 20 min post-14C administration samples of exhaled air showed a significantly higher amount of 14C activity than for the rest of the children, that is 6% and 19% of administered activity exhaled per hour compared with 0.3–0.9% (mean 0.5%) of administered activity exhaled per hour indicating that these two children that is were HP positive. For a 3-year-old HP positive child, absorbed dose to the urinary bladder wall was 0.3 mGy MBq-1 and effective dose per unit of administered activity was 0.4 mSv MBq-1. Using 55 kBq, which is a normal amount for older children when liquid scintillation counters are used for measurement, the effective dose will be approximately 6 µSv to a 3-year-old HP negative child and 20 µSv to a HP positive child. Thus there is no reason for restrictions on performing a normal 14C urea breath test, even on young children.
